BWXT Medical, TRIUMF ink medical isotope production deal

By staff writers

June 14, 2022 -- BWXT Medical and Canada's particle accelerator center TRIUMF have executed a licensing and services agreement that will expand their existing medical isotope production partnership.

The agreement will enable BWXT Medical to manufacture actinium-225 (Ac-225)-based products for pharmaceutical companies developing targeted alpha therapeutics. After TRIUMF irradiates thorium-232 targets, BWXT will then process and produce high-purity Ac-225 for commercial sale, according to the vendor

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking